{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=13&sponsor=Pfizer",
    "query": {
      "sponsor": "Pfizer",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 3276,
    "total_pages": 328,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=14&sponsor=Pfizer&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=12&sponsor=Pfizer&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T15:07:24.066Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02880371",
      "title": "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ARRY-382",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2016-09-01",
      "completion_date": "2019-10-24",
      "has_results": true,
      "last_update_posted_date": "2022-06-16",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 30,
      "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02880371"
    },
    {
      "nct_id": "NCT04389632",
      "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small Cell Lung",
        "Squamous Cell Carcinoma of Head and Neck",
        "HER2 Negative Breast Neoplasms",
        "Esophageal Squamous Cell Carcinoma",
        "Esophageal Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Ovarian Neoplasms",
        "Cutaneous Squamous Cell Cancer",
        "Exocrine Pancreatic Adenocarcinoma",
        "Urinary Bladder Neoplasms",
        "Uterine Cervical Neoplasms",
        "Stomach Neoplasms"
      ],
      "interventions": [
        {
          "name": "sigvotatug vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1006,
      "start_date": "2020-06-08",
      "completion_date": "2029-03-22",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 106,
      "location_summary": "Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04389632"
    },
    {
      "nct_id": "NCT00645398",
      "title": "A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 751,
      "start_date": "2004-09",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 81 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00645398"
    },
    {
      "nct_id": "NCT02255565",
      "title": "Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "ADHD",
        "Autism"
      ],
      "interventions": [
        {
          "name": "Very Low Dose Quillivant XR",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Quillivant XR",
          "type": "DRUG"
        },
        {
          "name": "Moderate Dose Quillivant XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "5 Years to 16 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-09",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02255565"
    },
    {
      "nct_id": "NCT01976364",
      "title": "Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Psoriatic"
      ],
      "interventions": [
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 686,
      "start_date": "2014-02-17",
      "completion_date": "2019-05-20",
      "has_results": true,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01976364"
    },
    {
      "nct_id": "NCT05038982",
      "title": "Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prurigo Nodularis",
        "Pruritus",
        "Chronic Pruritus",
        "Chronic Prurigo",
        "Skin Diseases"
      ],
      "interventions": [
        {
          "name": "Abrocitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-09",
      "completion_date": "2022-07-11",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05038982"
    },
    {
      "nct_id": "NCT02118792",
      "title": "Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "AN2728 Topical Ointment, 2%",
          "type": "DRUG"
        },
        {
          "name": "Matching vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 764,
      "start_date": "2014-03",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 1,
      "location_summary": "Henrico, Virginia",
      "locations": [
        {
          "city": "Henrico",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02118792"
    },
    {
      "nct_id": "NCT03722966",
      "title": "Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        },
        {
          "name": "Oral Nicotine Replacement Therapy (NRT)",
          "type": "DRUG"
        },
        {
          "name": "Medication Reminders",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Tobacco Cessation Counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-01-07",
      "completion_date": "2022-02-07",
      "has_results": true,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03722966"
    },
    {
      "nct_id": "NCT00170053",
      "title": "Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 177,
      "start_date": "2005-06",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2012-07-31",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00170053"
    },
    {
      "nct_id": "NCT02841267",
      "title": "A Trial of PF-06252616 in Ambulatory Participants With LGMD2I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "LGMD2I"
      ],
      "interventions": [
        {
          "name": "PF 06252616",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kathryn Wagner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 19,
      "start_date": "2016-07",
      "completion_date": "2019-01",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-27T15:07:24.066Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02841267"
    }
  ]
}